Our findings highlighted the notable superiority of BJO-assisted TACE over standalone TACE, particularly in terms of improving the clinical benefit rate (CBR), quality of life, alpha-fetoprotein (AFP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), and vascular endothelial growth factor (VEGF) levels in liver cancer patients. The gene discussed is GPT; the disease is liver cancer.